logo
Patient Monitoring Market Size is Projected to Reach USD 112.47 Billion by 2033, Growing at a CAGR of 7.3%: Straits Research

Patient Monitoring Market Size is Projected to Reach USD 112.47 Billion by 2033, Growing at a CAGR of 7.3%: Straits Research

Yahoo27-01-2025

The global patient monitoring market size was valued at USD 55.60 billion in 2024 and is projected to reach from USD 59.66 billion in 2025 to USD 112.47 billion by 2033, growing at a CAGR of 7.3% during the forecast period (2025-2033).
New York, United States, Jan. 27, 2025 (GLOBE NEWSWIRE) -- A set of instruments known as a patient monitoring system enables medical professionals to monitor a patient's health. These gadgets—remote physiologic monitoring—are routinely used for remote patient monitoring. Utilizing digital technology, they gather and track patient health data, transmit it electronically to healthcare specialists, and use it to aid in condition evaluation, diagnosis, and treatment. This technology alters how healthcare is delivered in the US by reducing costs and improving patient outcomes. Patient monitoring systems are easier to define in terms of their uses.
One well-known example of a patient monitoring system is electrocardiography (ECG), which records the heart's electrical activity. Hypertensive patients use monitoring tools to keep an eye on their blood pressure. People with diabetes utilize glucose monitoring equipment to assess blood glucose levels and prevent potentially dangerous consequences. Patients with chronic obstructive pulmonary disease (COPD), asthma, and other respiratory conditions also require monitoring equipment.
Download Free Sample Report PDF @ https://straitsresearch.com/report/patient-monitoring-market/request-sample
Market Dynamics
Growing Adoption of Remote Patient Monitoring Drives the Global Market
Recent years have seen a significant increase in the usage of patient monitoring devices for continuous vital sign monitoring and analysis, particularly during the COVID-19 outbreak. Patient monitoring systems enable medical personnel to monitor patients' health remotely or at home. Healthcare can become more digitalized to lower costs and boost revenue for medical practices. Additionally, remote monitoring equipment that provided medical treatment in a comfortable setting and permitted remote monitoring from patients' homes was helpful for non-COVID-19 patients who needed chronic care. This increased the number of beds and other important clinical resources available in hospitals and other healthcare facilities for patients who required immediate on-site care.
Due to stringent government regulations and favorable laws for patient monitoring equipment, it is anticipated that many organizations will be motivated to develop novel pharmaceuticals for treating chronic diseases like cardiovascular and respiratory diseases, cancers, diabetes, and chronic respiratory diseases. The widespread use of patient monitoring tools in clinical research trials and the convenience of monitoring is made possible by the market penetration of these tools, which hastens the development of novel medications. The increased prevalence of chronic diseases directly impacts the utilization of ICUs. Due to the benefits offered by patient monitoring devices, such as shorter hospital stays, fewer adverse effects, and speedier recovery times, the market is predicted to grow profitably.
Rising Demand in Non-Hospital Creates Tremendous Opportunities
The sustainability of the current healthcare system is a serious worry for governments worldwide. Due to escalating healthcare expenditures, particularly in hospital settings, the focus has recently switched to alternative treatment modalities, including home healthcare. In addition, the frequency of hospital readmissions has dramatically decreased since the introduction of remote and home monitoring technology. There is consequently a growing demand for effective home medical devices, such as fetal and neonatal monitors, ECG recorders, temperature monitors, pulse oximeters, and event monitors.
Regional Analysis
North America is the most significant patient monitoring market shareholder and is estimated to exhibit a CAGR of 8.1% over the forecast period. 42.7% of the market for patient monitoring devices was in North America. This results from several things: its well-established healthcare infrastructure, high healthcare spending, monopolistic market participants, and the rapid adoption of cutting-edge technologies. North America has the most developed medical equipment market worldwide. The market is anticipated to be driven by the quick adoption of patient monitoring and homecare devices for routine, continuous, and long-term patient monitoring and reducing the number of hospital visits during the projected period.
Additionally, favorable payment terms are expected to accelerate market expansion. Additional factors anticipated to drive market expansion include the rise in accidents, sports injuries, and health problems associated with lifestyle. Increased emergency care needs and increased usage of mobile surgery centers are expected to drive the market during the forecasted period.
Europe is anticipated to exhibit a CAGR of 8.4% over the forecast period. Europe accounted for 25.1% of the global market for patient monitoring devices in 2020. Europe's market includes countries including Germany, France, Italy, Spain, and the United Kingdom. The increasing demand for patient monitoring devices and central data management systems for accurate information and medical services is expected to boost the market. Market expansion is fueled by the prevalence of diseases and the growing older population. In 2020, more than one-fifth of people in Europe were over 65.
In Europe, the leading cause of illness and mortality is chronic disease. The requirement for patient monitoring devices has increased due to the number of patients admitted to healthcare facilities. The COVID-19 pandemic has increased the usage of patient monitoring devices and remote monitoring to assess and analyze vital signs in healthcare settings. To obtain more exact and accurate results economically, advanced patient monitoring devices are constantly being developed and presented by various market participants. As a result, the market for patient monitoring devices is anticipated to grow during the period in question.
Ask for Customization @ https://straitsresearch.com/report/patient-monitoring-market/request-sample
Key Highlights
The global patient monitoring market size was valued at USD 55.60 billion in 2024 and is projected to reach from USD 59.66 billion in 2025 to USD 112.47 billion by 2033, growing at a CAGR of 7.3% during the forecast period (2025-2033).
Based on the product, the global patient monitoring market is bifurcated into blood glucose monitoring systems, cardiac monitoring devices, multiparameter monitoring devices, respiratory monitoring devices, temperature monitoring devices, hemodynamic/pressure monitoring devices, fetal neonatal monitoring devices, neuromonitoring devices, weight monitoring devices, other. The blood glucose segment dominates the global market and is projected to exhibit a CAGR of 9.1% over the forecast period.
Based on end-users, the global patient monitoring market is divided into Hospitals, Ambulatory Surgery Centers, Home Care Settings, and Others. The hospital segment is the most significant contributor to the market and is estimated to exhibit a CAGR of 8.2% over the forecast period.
North America is the most significant global patient monitoring market shareholder and is estimated to exhibit a CAGR of 8.1% over the forecast period.
Competitive Players
Abbott
Boston Scientific
Medtronic
Philips
Nihon Kohden Health Anywhere Inc.
Koninklijke Philips N.V.
G.E. Healthcare
MASIMO CORPORATION
Smiths Medical
Bosch
Biotronik
Intel
Welch Allyn
Recent Developments
In June 2023, With the introduction of its Generation (Gen) 1 device, medical diagnostic company Know Labs provides the first non-invasive glucose monitor. The Generation (Gen) 1 gadget prototype uses radio waves and machine learning algorithms to measure blood sugar levels through the skin.
In May 2023, Royal Philips, a global leader in health technology, and Masimo, a global medical technology company, announced FDA clearance for SedLine® Brain Function Monitoring, Regional Oximetry (O3®), and CO2 measurements in Philips Patient Monitors – IntelliVue MX750 and MX850. The latest extension will let clinicians make quick and informed judgments without additional monitoring equipment.
Segmentation
By Product
Blood Glucose Monitoring Systems
Cardiac Monitoring Devices
Multiparameter Monitoring Devices
Respiratory Monitoring Devices
Temperature Monitoring Devices
Hemodynamic/Pressure Monitoring Devices
Fetal and Neonatal Monitoring Devices
Neuromonitoring Devices
Weight Monitoring Devices
By End-User
Hospitals
Ambulatory Surgery Centers
Home Care Settings
By Region
North America
Europe
Asia-Pacific
Latin America
The Middle East and Africa
Get Detailed Market Segmentation @ https://straitsresearch.com/report/patient-monitoring-market/segmentation
About Straits Research Pvt. Ltd.
Straits Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers. Straits Research Pvt. Ltd. provides actionable market research data, especially designed and presented for decision making and ROI.
Whether you are looking at business sectors in the next town or crosswise over continents, we understand the significance of being acquainted with the client's purchase. We overcome our clients' issues by recognizing and deciphering the target group and generating leads with utmost precision. We seek to collaborate with our clients to deliver a broad spectrum of results through a blend of market and business research approaches.
Phone: +1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
Email: sales@straitsresearch.com
Follow Us: LinkedIn | Facebook | Instagram | Twitter

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

PeterMD Announces Official Website Update Featuring Telemedicine Services for Men's Hormone Health and TRT Support
PeterMD Announces Official Website Update Featuring Telemedicine Services for Men's Hormone Health and TRT Support

Yahoo

time27 minutes ago

  • Yahoo

PeterMD Announces Official Website Update Featuring Telemedicine Services for Men's Hormone Health and TRT Support

National Platform Offers Secure Access to Physician-Led TRT and Hormone Health Consultations from Anywhere in the U.S. VERO BEACH, June 10, 2025 (GLOBE NEWSWIRE) -- PeterMD, a Florida-based men's health telemedicine provider, has updated its official website to spotlight its nationwide services focused on testosterone replacement therapy (TRT), hormone optimization, and performance support. Available in all 50 states, PeterMD offers direct-to-consumer access to licensed providers via a secure digital platform. According to the official website ( PeterMD allows adult men to privately consult with certified TRT specialists, receive personalized treatment plans based on lab results, and manage therapy from the comfort of home. Services are available without insurance requirements, with fast turnaround times and HIPAA-compliant care. 'PeterMD was built to eliminate unnecessary barriers to men's health,' said a company spokesperson. 'We believe in transparent, physician-directed care that gives men control over their wellness without waiting rooms or stigma.' The telemedicine platform includes options for lab testing coordination, treatment supervision, and ongoing patient support. Every consultation is handled by a qualified medical professional trained in men's hormone health. Once a plan is approved, therapies are shipped directly with complete oversight from the PeterMD medical team. The updated site features secure registration, FAQs, and real-time access to specialists. New clients are invited to speak directly with a TRT specialist by calling or texting 772-800-6133. For existing patients, dedicated support is available at 772-444-8669 or via email at support@ PeterMD patient support hours: Monday–Sunday: 7 AM – 7 PM EST (for new inquiries) Monday–Friday: 9 AM – 5 PM EST (for existing patients) About PeterMD PeterMD is a telehealth provider based in Vero Beach, Florida, offering customized men's hormone and wellness solutions across the United States. The platform connects users with medical experts for private, fast, and clinically guided treatment—empowering men to reclaim their energy, focus, and vitality through modern, accessible care. Product and Contact Information Brand: PeterMDWebsite: support@ (New Patients): 772-800-6133Phone (Support): 772-444-8669Mailing Address: 601 21st Street, Suite 300, Vero Beach, FL, United StatesBusiness Hours:New Patients: Monday–Sunday, 7 AM – 7 PM ESTSupport: Monday–Friday, 9 AM – 5 PM EST Disclaimer This release is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. All medical decisions should be made in consultation with a licensed healthcare provider. Availability of telemedicine services may vary by state. PeterMD complies with all applicable healthcare regulations. CONTACT: Email: support@ Phone (New Patients): 772-800-6133 Phone (Support): 772-444-8669Sign in to access your portfolio

Trump's First Surgeon General: RFK Jr. Purging the CDC Advisory Committee Will Put Lives at Risk
Trump's First Surgeon General: RFK Jr. Purging the CDC Advisory Committee Will Put Lives at Risk

Time​ Magazine

time36 minutes ago

  • Time​ Magazine

Trump's First Surgeon General: RFK Jr. Purging the CDC Advisory Committee Will Put Lives at Risk

When Secretary Robert F. Kennedy Jr. began his tenure as Health and Human Services Secretary, he pledged, 'We won't take away anyone's vaccines.' However, recent policy changes under his leadership—coupled with the unprecedented dismissal of all 17 members of the CDC's Advisory Committee on Immunization Practices (ACIP) on June 9—have proven that statement false, raising grave concerns for our nation's COVID-19 response and broader vaccine policies. These shifts not only jeopardize public health but also threaten to erode trust in our health institutions at a critical time. In May 2025, the Food and Drug Administration (FDA) introduced a new COVID-19 vaccine framework, limiting access to updated vaccines for Americans aged 65 and older or those with specific risk factors. Furthermore, Secretary Kennedy announced that the Centers for Disease Control and Prevention (CDC) would no longer recommend COVID-19 vaccines for 'healthy' children or pregnant women—bypassing the standard ACIP review process. Compounding these changes, the abrupt removal of ACIP's entire panel of independent experts, who have guided evidence-based vaccine policy for decades, risks destabilizing a cornerstone of public health. These actions collectively restrict access to a vital tool for saving lives and undermine confidence in our health systems. During my tenure as Surgeon General under the first Trump administration, we faced significant public health challenges, from addressing the opioid epidemic by increasing access to Naloxone to launching Operation Warp Speed for the COVID-19 vaccine development effort. The vaccines developed under Trump's first term have proven to be one of our most effective defenses against COVID-19; yet, the current administration's new policies limit their availability, potentially leaving millions vulnerable. The dismissal of ACIP's experts—without a clear plan for replacing them with qualified scientists—further jeopardizes trust in the institutions tasked with protecting Americans. The major flaw in the new vaccine framework is its narrow assessment of risk. Although the immediate dangers of COVID-19 have lessened, it remains a leading cause of death and hospitalization, claiming nearly 50,000 lives in the U.S. in 2024—more than breast cancer or car accidents. The fact is, 75% of Americans have risk factors, such as obesity or diabetes, that increase their vulnerability to severe COVID outcomes. However, the burden is now placed on individuals to self-identify as high risk, creating confusion and inconsistency in access. Unlike other countries with centralized systems for identifying at-risk individuals, the U.S. expects patients—many of whom lack easy access to healthcare—to navigate eligibility alone. Risk assessment should also consider individual circumstances beyond underlying health conditions. A 58-year-old bus driver or healthcare worker faces significantly greater exposure than someone working remotely. By limiting vaccines to specific groups based solely on preexisting health status, the policy overlooks these critical contextual differences. Secretary Kennedy's team argues that there is insufficient evidence to support updated COVID-19 vaccines for healthy Americans under 65, but this claim is flatly unfounded. Years of real-world data demonstrate that vaccines save lives and reduce hospitalizations across all age groups. During the 2023 to 2024 fall and winter season, 95% of those hospitalized for COVID had not received an updated vaccine. While the administration cites other countries' more restrictive vaccine policies, such comparisons ignore the unique health landscape in the U.S., which includes higher obesity rates, worse maternal health outcomes, and uneven healthcare access. The policy also neglects the issue of Long COVID, which affects millions with debilitating symptoms lasting months or years. Though older adults are at higher risk for severe acute infections, Long COVID disproportionately impacts adults aged 35 to 49—and children are also affected. Vaccination reduces the risk of developing Long COVID, an essential reason many healthy individuals choose to stay up-to-date with their vaccines. Particularly concerning is the decision to end COVID vaccine recommendations for 'healthy' pregnant women, which contradicts the FDA's own guidance. Pregnant women face heightened risks of severe COVID outcomes, including death, pre-eclampsia, and miscarriage. Vaccination during pregnancy is crucial—not just for maternal health but also for protecting infants under six months, who cannot be vaccinated and rely on maternal antibodies for protection. Decades of research confirm that vaccines, including COVID vaccines, safely transfer antibodies to newborns, lowering their risk of severe illness. The dismissal of ACIP's members amplifies these concerns. ACIP has been a trusted, science-driven body that ensures vaccines are safe and effective, saving countless lives through its transparent recommendations. Its members, rigorously vetted for expertise and conflicts of interest, provide independent guidance critical to public health. Removing them without clear evidence of misconduct risks replacing qualified scientists with less experienced voices. This move fuels vaccine hesitancy and skepticism about public health decisions, particularly when paired with the bypassing of ACIP's review process for the new COVID vaccine policies. These changes create uncertainty about who can access vaccines. Without clear CDC recommendations, insurance companies may impose their own coverage criteria, potentially increasing costs for a vaccine that was previously free for most Americans. Healthcare providers, lacking federal guidance and ACIP's expertise, may struggle to advise patients, leading to a confusing and inequitable system that limits choice—hardly the 'medical freedom' Secretary Kennedy claims to champion. Ultimately, these actions threaten to erode trust in public health. FDA officials argue the new framework enhances transparency, yet bypassing ACIP's review and dismissing its members undermines that aim. Extensive data demonstrate that updated vaccines lower hospitalization and death rates, yet this evidence was sidelined. Such actions breed skepticism, making it harder to unite Americans around shared health goals. The stakes are high, but a better path is possible. Restoring trust requires transparent, evidence-based policymaking that prioritizes access to life-saving tools. I urge Secretary Kennedy and the administration to reconsider this framework, reinstate ACIP's role in vaccine policy, and ensure any new appointees are qualified, independent experts. If concerns about ACIP exist, they should be addressed through reform, not dissolution. Healthcare providers and community leaders must also educate patients about vaccination benefits, particularly for vulnerable groups like pregnant women and those with high exposure. Individuals can take action by staying informed, discussing vaccination with their doctors, and advocating for clear, equitable access to vaccines. By working together—government, providers, and citizens—we can protect lives, reduce the burden of Long COVID, and rebuild confidence in our public health system. We must seize this opportunity to unite around science and ensure a healthier, safer, and prosperous future for all Americans.

The Memory Breath Releases Latest Customer Reviews Using This Daily Breathing Ritual
The Memory Breath Releases Latest Customer Reviews Using This Daily Breathing Ritual

Yahoo

time41 minutes ago

  • Yahoo

The Memory Breath Releases Latest Customer Reviews Using This Daily Breathing Ritual

Website Update Showcases Affordable Digital Ritual for Focus and Mental Clarity Without Pills or Supplements New York, June 10, 2025 (GLOBE NEWSWIRE) -- The Memory Breath, a digital wellness brand focused on natural brain support, has updated its official website to showcase the latest customer feedback surrounding its daily breathing ritual audio. Designed to support calm clarity and cognitive balance, the non-pill format is now accessible online as an easy-to-use digital experience. According to the official website ( The Memory Breath is not a supplement, but a guided digital audio sequence developed to align with the body's natural neurological rhythms. The brand positions its routine as an accessible, affordable alternative to high-priced cognitive supplements—without the need for capsules, additives, or restrictive programs. 'The simplicity of this ritual is what sets it apart—it's sound-based, soothing, and rooted in the body's natural patterns,' said a company spokesperson. 'We're committed to making natural brain support accessible without relying on unproven pills.' The company notes that this audio-guided approach is intended to help activate a neurological pathway referred to as 'BNO,' linked to focus, memory, and mental clarity. According to internal testing, the ritual may support up to 20x greater engagement with this pathway compared to certain popular supplements, although individual results may vary. Recent updates to the website include new customer insights, simplified access to the program, and an overview of the intended wellness applications of the audio routine. The Memory Breath includes a satisfaction guarantee and direct support for first-time users. About The Memory Breath The Memory Breath is a digital-first wellness brand offering audio-based rituals designed to support focus, mental clarity, and natural cognitive balance. Rooted in simplicity and sound science, the brand avoids pills and embraces accessible, non-invasive approaches to everyday wellness. Product and Contact Information Brand: The Memory BreathWebsite: support@ Service: 1-800-390-6035 Disclaimer This release is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. The statements made about this product have not been evaluated by the Food and Drug Administration. Individual results may vary. Consumers should consult a qualified healthcare provider before beginning any new wellness routine. CONTACT: Email: support@ Customer Service: 1-800-390-6035Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store